Literature DB >> 8753689

99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue.

E Derebek1, Z Kirkali, A S Dogan, B Degirmenci, M Yilmaz, E Igci, K Yorukoglu, I Kovanlikaya, H Durak.   

Abstract

Technetium-99m hexakis-2-methoxyisobutylisonitrile (MIBI) and thallium-201 imaging was performed in a patient with metastatic renal cell carcinoma (RCC), which is a well-known tumour type demonstrating P1-glycoprotein (PGP) overexpression. Two scintigraphic patterns - Tl(+)/MIBI(-) in primary tumour and Tl(+)/MIBI(+) in metastatic tumour - were observed, suggesting high- and low-level PGP expression, respectively. Immunochemical study for PGP revealed strong staining of the primary tumour cells. This case clinically validates the previously suggested relationship between 99mTc-MIBI uptake and PGP expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8753689     DOI: 10.1007/bf01084374

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  13 in total

Review 1.  Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma?

Authors:  D A Swanson
Journal:  Semin Urol       Date:  1993-02

2.  Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes.

Authors:  D Piwnica-Worms; B L Holman
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

Review 3.  Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.

Authors:  A E Chapman; L J Goldstein
Journal:  Semin Oncol       Date:  1995-02       Impact factor: 4.929

4.  Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; H Goldschmidt; W J Lorenz; W Maier-Borst; G van Kaick
Journal:  Eur J Nucl Med       Date:  1995-05

5.  Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer?

Authors:  J L Moretti; M Caglar; C Boaziz; N Caillat-Vigneron; J F Morere
Journal:  Eur J Nucl Med       Date:  1995-02

6.  Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype.

Authors:  C F Rochlitz; H Lobeck; S Peter; J Reuter; B Mohr; E de Kant; D Huhn; R Herrmann
Journal:  Cancer       Date:  1992-06-15       Impact factor: 6.860

7.  Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

Authors:  A T Fojo; D W Shen; L A Mickley; I Pastan; M M Gottesman
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

8.  Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.

Authors:  K Nishiyama; T Shirahama; A Yoshimura; T Sumizawa; T Furukawa; M Ichikawa-Haraguchi; S Akiyama; Y Ohi
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

9.  Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.

Authors:  V V Rao; M L Chiu; J F Kronauge; D Piwnica-Worms
Journal:  J Nucl Med       Date:  1994-03       Impact factor: 10.057

10.  Detection of drug resistance and P-glycoprotein in human renal cell carcinomas.

Authors:  M Bak; T Efferth; G Mickisch; J Mattern; M Volm
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

View more
  2 in total

Review 1.  99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide.

Authors:  Scott P Campbell; Antonios Tzortzakakis; Mehrbod S Javadi; Mattias Karlsson; Lilja B Solnes; Rimma Axelsson; Mohamad E Allaf; Michael A Gorin; Steven P Rowe
Journal:  Br J Radiol       Date:  2018-02-27       Impact factor: 3.039

2.  Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma.

Authors:  Steven P Rowe; Michael A Gorin; Jennifer Gordetsky; Mark W Ball; Phillip M Pierorazio; Takahiro Higuchi; Jonathan I Epstein; Mohamad E Allaf; Mehrbod S Javadi
Journal:  Clin Nucl Med       Date:  2015-04       Impact factor: 7.794

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.